skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
Solitomab (Code C77854)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Solitomab

Definition: A recombinant bispecific monoclonal antibody directed against both CD3 and epithelial cell adhesion molecule (EpCAM) with potential immunomodulating and antineoplastic activities. Solitomab attaches to both CD3-expressing T lymphocytes and EpCAM-expressing tumor cells, thereby selectively cross-linking tumor and T lymphocytes; this may result in the recruitment of cytotoxic T lymphocytes (CTL) to T lymphocyte/tumor cell aggregates and the CTL-mediated death of EpCAM-expressing tumor cells. CD3 is an antigen expressed on mature T cells; EpCAM, a cell surface protein, is expressed by a variety of tumor cells and is frequently found in head and neck cancers.

Label: Solitomab

NCI Thesaurus Code: C77854 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: CL383556  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)

External Source Codes: 
CAS Registry Number 1005198-65-1 (see NLM ChemIDplus info)
FDA UNII Code ZQQ51B5708
PDQ Closed Trial Search ID 592863
PDQ Open Trial Search ID 592863 (check for NCI PDQ open clinical trial info)

Other Properties:
     Name Value (qualifiers indented underneath)
code C77854
Contributing_Source FDA
Legacy_Concept_Name Anti-EpCAM_Anti-CD3_Recombinant_Bispecific_Monoclonal_Antibody_MT110
Semantic_Type Amino Acid, Peptide, or Protein
Semantic_Type Immunologic Factor

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom